Rezolute

Rezolute (operating at rezolutebio.com) is a rare disease company engineered for developing treatments. Founded in Not specified and headquartered in Redwood City, CA, Rezolute is focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. Under the hood, the company is advancing therapies for serious rare diseases, including a monoclonal antibody that binds to the insulin receptor to decrease over-activation by insulin and related substances. This allows patients to receive effective treatments for their conditions. Backed by undisclosed funding.